Polymyalgia rheumatica and giant cell arteritis

Rheumatic Disease Clinics of North America

Volumn 26, Issue 3, 2000, Pages 493-515

  Evans, Jonathan M ^a   Hunder, Gene G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 6; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TENIDAP;

CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG POTENTIATION; ERYTHROCYTE SEDIMENTATION RATE; GIANT CELL ARTERITIS; HUMAN; INCIDENCE; LIFE EXPECTANCY; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATIC POLYMYALGIA; TREATMENT OUTCOME;

EID: 0033845322     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70153-8     Document Type: Article

References (84)

1. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?
2. Increased prevalence of HLA-DR4 in giant cell arteritis
3. CD8 lymphocyte subsets in active polymyalgia rheumatica: Comparison with elderly-onset and adult rheumatoid arthritis and influence of prednisone therapy
4. Clinical manifestations of giant cell (temporal) arteritis
5. Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis
6. A longitudinal study of anticardiolipin antibody in polymyalgia rheumatica and giant cell arteritis
7. Polymyalgia rheumatica: A 10-year epidemiologic and clinical study
8. Drug prescribing in the elderly
9. Von Willebrand factor in the outcome of temporal arteritis
10. Increased incidence of antibodies to adenovirus and respiratory syncytial virus in polymyalgia rheumatica
11. The association of plasma IL-6 levels with functional disability in community-dwelling elderly
12. An initially double-blind controlled 96-week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica
13. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica
14. Giant cell arteritis and thyroid dysfunction: Multicenter case-control study
15. Giant cell arteritis and cardiovascular risk factors: A multicenter, prospective case-control study
16. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark: Association with epidemics of Mycoplasma pneumoniae infections
17. Persistent giant cell arteritis despite corticosteroid treatment
18. Thoracic aortic aneurysm and rupture in giant cell arteritis
19. The implications of recognizing large-vessel involvement in elderly patients with giant cell arteritis
20. Increased incidence of Aortic aneurysm and dissection in patients with Giant Cell Arteritis: A population based study
21. Polymyalgia and giant cell arteritis in emergency department patients
22. The use of methotrexate in polymyalgia rheumatica
23. Methotrexate in polymyalgia rheumatica: Preliminary results of an open, randomized study
24. Atypical presentations of polymyalgia rheumatica
25. Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis
26. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis
27. Pleural effusion as a form of presentation of temporal arteritis
28. Elastase derived elastin peptides: Putative autoimmune targets in giant cell arteritis
29. Permanent visual loss and cerebrovascular accidents in giant cell arteritis
30. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate
31. Visual loss in giant cell arteritis
32. Molecular analysis of HLA-DR polymorphism in polymyalgia rheumatica
33. Polymyalgia rheumatica is associated with both HLA-DRB1*401 and HLADRB1*0404
34. Giant cell arteritis: Validity and reliability of various diagnostic criteria
35. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate
36. Giant cell arteritis and polymyalgia rheumatica
37. The ACR 1990 Criteria for the classification of GCA
38. Giant cell arteritis and polymyalgia rheumatica
39. A genetic approach to the aetiology of giant ceil arteritis: Depletion of the CD8+ T-lymphocyte subset in relatives of patients with polymyalgia rheumatica and arteritis temporalis
40. Cytidine deaminase may be a useful marker in differentiating elderly onset rheumatoid arthritis from polymyalgia/giant cell arteritis
41. Skip lesions in temporal arteritis
42. Large artery involvement in giant cell (temporal) arteritis
43. C-reactive protein in rheumatology
44. Respiratory tract symptoms as a clue to giant cell arteritis
45. Color doppler sonography of the temporal arteries in giant cell arteritis and polymyalgia rheumatica
46. When is arteritis of the temporal arteries not temporal arteritis?
47. Absence of anti-beta2 glycoprotein I antibodies in giant cell arteritis: A study of 45 biopsy-proven cases
48. Steroid sparing activity of tenidap in patients with polymyalgia rheumatica: A multicenter double blind randomized placebo controlled study
49. Visual morbidity in giant cell arteritis: Clinical characteristics and prognosis for vision
50. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota 1950-1985
51. Anticardiolipin antibodies in giant cell arteritis and polymyalgia rheumatica: A study of 40 cases
52. The inflammatory infiltrate in giant cell arteritis selects against B lymphocytes
53. Recognition of tissue residing antigen by T cells in vasculitic lesions of giant cell arteritis
54. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology Giant Cell Arteritis Classification Criteria cohort
55. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica
56. Clinical differentiation between giant cell (temporal) arteritis and Takayasu's arteritis
57. Prevention of blindness in giant cell arteritis by corticosteroid treatment
58. The influence of sectional interval on the reliability of temporal arterial biopsies in polymyalgia rheumatica
59. A follow-up study of polymyalgia rheumatica: Evidence of chronic axial synovitis
60. Erythrocyte sedimentation rate (ESR) at presentation is a prognostic indicator for duration of treatment in polymyalgia rheumatica
61. Circulating levels of IL-1B, IL-6, and Soluble IL-2 Receptor in polymyalgia rheumatica and giant cell arteritis and rheumatoid arthritis
62. Lingual and scalp infarction as a manifestation of giant cell arteritis: Delay in diagnosis leading to blindness
63. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis
64. Giant cell arteritis as a cause of death: Report of nine cases
65. Proximal bursitis in active polymyalgia rheumatica
66. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis
67. Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica
68. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota 1970-1991
69. The incidence of giant cell arteritis in Olmsted County, Minnesota: Apparent fluctuations in a cyclic pattern
70. Epidemiology and mortality in 220 patients with polymyalgia rheumatica
71. The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica
72. GB Virus C in systemic medium- and small-vessel necrotizing vasculitides
73. Association of parvovirus B19 infection with giant cell arteritis
74. Elevated levels of 92-kd type IV collagenase (matrix metalloproteinase 9) in giant cell arteritis
75. Giant cell arteritis as an antigen-driven disease
76. Molecular approaches toward pathologic mechanisms in giant cell arteritis and Takayasu's arteritis
77. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis
78. Detection of active cytomegalovirus infection in inflammatory aortic aneurysms with RNA polymerase chain reaction
79. Lymphomatous perivascular infiltration involving the temporal artery
80. Antibodies against Chlamydia pneumoniae, cytomegalovirus, enteroviruses and respiratory syncytial virus in patients with polymyalgia rheumatica
81. HLA antigens in polymyalgia rheumatica in Northern Sweden
82. Cytokines and adhesion molecules in patients with polymyalgia rheumatica
83. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
84. Clinical usefulness of temporal artery biopsy